10-Q quarterly report · filed Nov 5, 2026

Vera Therapeutics, Inc. (VERA) Q3 2026 10-Q Quarterly Report

Short answer

Vera Therapeutics, Inc. (VERA) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $10M with net income of −$94M.

Q3 2026 key financials · XBRL

Revenue
$10M
Net income
−$94M
−16.7% YoY · +14.4% QoQ
Operating margin
-931.2%
EPS (diluted)
−$1.29
−2.4% YoY · +15.7% QoQ

Source: XBRL data from the Vera Therapeutics, Inc. (VERA) Q3 2026 10-Q on SEC EDGAR. USD.

Vera Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $10.3M, versus $0 YoY, entirely from TRUTAKNA sales
  • Gross margin 68%, based on $10.3M revenue and $3.3M cost of sales
  • Net loss $93.7M vs $80.3M YoY, with operating expenses $106.0M vs $83.9M
  • Cash, equivalents and marketable securities $384.0M vs $714.6M at December 31, 2025
  • Nine-month operating cash outflow $305.9M vs $171.1M, with $9.6M financing inflow and $75.0M debt draw in October 2026
  • Near-term outlook: continued losses and rising R&D, SG&A and capital expenditures, with liquidity expected for at least 12 months

Risk Factors

  • Newly heightened commercialization risk: FDA accelerated approval of TRUTAKNA on July 7, 2026 created post-approval study and commercial execution obligations
  • Regulatory risk: confirmatory eGFR study failure could trigger accelerated-approval withdrawal after approval based on UPCR results
  • Operational risk: limited commercialization experience and newly building sales, market-access, and distribution capabilities
  • Competitive risk: Roche’s GAZYVA received FDA Priority Review in July 2026 for pMN, with a decision expected by November 2026
  • Financial risk: $150.0 million outstanding under the 2025 Loan Agreement as of October 31, 2026, with covenant-related acceleration exposure

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Vera Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.